A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis comparing nab-paclitaxel plus carboplatin (nab-PC) with solvent-based paclitaxel plus carboplatin (sb-PC) in first-line advanced non-small cell lung cancer (NSCLC).
Corey J. Langer
Consultant or Advisory Role - Celgene
Vera Hirsh
Consultant or Advisory Role - Celgene
Research Funding - Celgene
Yin Wan
Research Funding - Celgene
Fang-Ju Lin
Research Funding - Celgene
Scott Whiting
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Research Funding - Celgene
Teng Jin Ong
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Marc Botteman
Research Funding - Celgene